James Lillie
Förmögenhet: 7 M $ per 2026-05-31
Förmögenhet: 7 M $ per 2026-05-31
James Lillie is Chief Scientific Officer at MapLight Therapeutics, Inc. since 2019.
Formerly, Dr. Lillie was Senior Director-Biology at Scriptgen Pharmaceuticals, Inc. and Chief Scientific Officer at OvaScience, Inc. in 2018.
Dr. Lillie earned a doctorate from Harvard University and completed undergraduate studies at Wesleyan University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-05-07 | 242 729 ( 0,57 % ) | 7 M $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2019-02-01 |
| Företag | Position | Slut |
|---|---|---|
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Teknisk/Vetenskaplig/F&U Direktör | 2018-12-07 |
Scriptgen Pharmaceuticals, Inc.
Scriptgen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Företagsledare/Principal | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Scriptgen Pharmaceuticals, Inc.
Scriptgen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wesleyan University
Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Health Technology |
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån